ArticleBreast cancer (Dove Medical Press)2026
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.
Zeliha Birsin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.